Company intelligence / Profile preview

SOM PROJECTS

Barcelona, Catalonia, Spainsom.com ↗

Ownership: Private
Employees: ~16
Development stage: Other

Overview

SOM Biotech has a proprietary AI-driven drug repurposing platform with two programs having completed Phase 2a/b clinical trials showing positive results. Lead asset SOM3355 demonstrated robust improvements in chorea for Huntington’s Disease patients with a favorable safety profile. The company also outlicensed its TTR amyloidosis program after successful Phase 2a results. Additional assets are at preclinical or early stages.

Therapeutic areas: Rare DiseasesNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Major research centersPharmaceutical companies

Beyond the preview

Go deeper on SOM PROJECTS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOM PROJECTS.

Explore the full profile